Cargando…

An Experimental Design Approach for Impurity Profiling of Valacyclovir-Related Products by RP-HPLC

Impurity profiling has become an important phase of pharmaceutical research where both spectroscopic and chromatographic methods find applications. The analytical methodology needs to be very sensitive, specific, and precise which will separate and determine the impurity of interest at the 0.1% leve...

Descripción completa

Detalles Bibliográficos
Autores principales: Katakam, Prakash, Dey, Baishakhi, Hwisa, Nagiat T, Assaleh, Fathi H, Chandu, Babu R, Singla, Rajeev K, Mitra, Analava
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Scientia Pharmaceutica 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318202/
https://www.ncbi.nlm.nih.gov/pubmed/25853072
http://dx.doi.org/10.3797/scipharm.1403-20
_version_ 1782355821998374912
author Katakam, Prakash
Dey, Baishakhi
Hwisa, Nagiat T
Assaleh, Fathi H
Chandu, Babu R
Singla, Rajeev K
Mitra, Analava
author_facet Katakam, Prakash
Dey, Baishakhi
Hwisa, Nagiat T
Assaleh, Fathi H
Chandu, Babu R
Singla, Rajeev K
Mitra, Analava
author_sort Katakam, Prakash
collection PubMed
description Impurity profiling has become an important phase of pharmaceutical research where both spectroscopic and chromatographic methods find applications. The analytical methodology needs to be very sensitive, specific, and precise which will separate and determine the impurity of interest at the 0.1% level. Current research reports a validated RP-HPLC method to detect and separate valacyclovir-related impurities (Imp-E and Imp-G) using the Box-Behnken design approach of response surface methodology. A gradient mobile phase (buffer: acetonitrile as mobile phase A and acetonitrile: methanol as mobile phase B) was used. Linearity was found in the concentration range of 50–150 μg/mL. The mean recovery of impurities was 99.9% and 103.2%, respectively. The %RSD for the peak areas of Imp-E and Imp-G were 0.9 and 0.1, respectively. No blank interferences at the retention times of the impurities suggest the specificity of the method. The LOD values were 0.0024 μg/mL for Imp-E and 0.04 μg/mL for Imp-G and the LOQ values were obtained as 0.0082 μg/mL and 0.136 μg/mL, respectively, for the impurities. The S/N ratios in both cases were within the specification limits. Proper peak shapes and satisfactory resolution with good retention times suggested the suitability of the method for impurity profiling of valacyclovir-related drug substances.
format Online
Article
Text
id pubmed-4318202
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Scientia Pharmaceutica
record_format MEDLINE/PubMed
spelling pubmed-43182022015-04-07 An Experimental Design Approach for Impurity Profiling of Valacyclovir-Related Products by RP-HPLC Katakam, Prakash Dey, Baishakhi Hwisa, Nagiat T Assaleh, Fathi H Chandu, Babu R Singla, Rajeev K Mitra, Analava Sci Pharm Research Article Impurity profiling has become an important phase of pharmaceutical research where both spectroscopic and chromatographic methods find applications. The analytical methodology needs to be very sensitive, specific, and precise which will separate and determine the impurity of interest at the 0.1% level. Current research reports a validated RP-HPLC method to detect and separate valacyclovir-related impurities (Imp-E and Imp-G) using the Box-Behnken design approach of response surface methodology. A gradient mobile phase (buffer: acetonitrile as mobile phase A and acetonitrile: methanol as mobile phase B) was used. Linearity was found in the concentration range of 50–150 μg/mL. The mean recovery of impurities was 99.9% and 103.2%, respectively. The %RSD for the peak areas of Imp-E and Imp-G were 0.9 and 0.1, respectively. No blank interferences at the retention times of the impurities suggest the specificity of the method. The LOD values were 0.0024 μg/mL for Imp-E and 0.04 μg/mL for Imp-G and the LOQ values were obtained as 0.0082 μg/mL and 0.136 μg/mL, respectively, for the impurities. The S/N ratios in both cases were within the specification limits. Proper peak shapes and satisfactory resolution with good retention times suggested the suitability of the method for impurity profiling of valacyclovir-related drug substances. Scientia Pharmaceutica 2014-05-05 2014 /pmc/articles/PMC4318202/ /pubmed/25853072 http://dx.doi.org/10.3797/scipharm.1403-20 Text en © Katakam et al.; licensee Österreichische Apotheker-Verlagsgesellschaft m. b. H., Vienna, Austria. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Katakam, Prakash
Dey, Baishakhi
Hwisa, Nagiat T
Assaleh, Fathi H
Chandu, Babu R
Singla, Rajeev K
Mitra, Analava
An Experimental Design Approach for Impurity Profiling of Valacyclovir-Related Products by RP-HPLC
title An Experimental Design Approach for Impurity Profiling of Valacyclovir-Related Products by RP-HPLC
title_full An Experimental Design Approach for Impurity Profiling of Valacyclovir-Related Products by RP-HPLC
title_fullStr An Experimental Design Approach for Impurity Profiling of Valacyclovir-Related Products by RP-HPLC
title_full_unstemmed An Experimental Design Approach for Impurity Profiling of Valacyclovir-Related Products by RP-HPLC
title_short An Experimental Design Approach for Impurity Profiling of Valacyclovir-Related Products by RP-HPLC
title_sort experimental design approach for impurity profiling of valacyclovir-related products by rp-hplc
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318202/
https://www.ncbi.nlm.nih.gov/pubmed/25853072
http://dx.doi.org/10.3797/scipharm.1403-20
work_keys_str_mv AT katakamprakash anexperimentaldesignapproachforimpurityprofilingofvalacyclovirrelatedproductsbyrphplc
AT deybaishakhi anexperimentaldesignapproachforimpurityprofilingofvalacyclovirrelatedproductsbyrphplc
AT hwisanagiatt anexperimentaldesignapproachforimpurityprofilingofvalacyclovirrelatedproductsbyrphplc
AT assalehfathih anexperimentaldesignapproachforimpurityprofilingofvalacyclovirrelatedproductsbyrphplc
AT chandubabur anexperimentaldesignapproachforimpurityprofilingofvalacyclovirrelatedproductsbyrphplc
AT singlarajeevk anexperimentaldesignapproachforimpurityprofilingofvalacyclovirrelatedproductsbyrphplc
AT mitraanalava anexperimentaldesignapproachforimpurityprofilingofvalacyclovirrelatedproductsbyrphplc
AT katakamprakash experimentaldesignapproachforimpurityprofilingofvalacyclovirrelatedproductsbyrphplc
AT deybaishakhi experimentaldesignapproachforimpurityprofilingofvalacyclovirrelatedproductsbyrphplc
AT hwisanagiatt experimentaldesignapproachforimpurityprofilingofvalacyclovirrelatedproductsbyrphplc
AT assalehfathih experimentaldesignapproachforimpurityprofilingofvalacyclovirrelatedproductsbyrphplc
AT chandubabur experimentaldesignapproachforimpurityprofilingofvalacyclovirrelatedproductsbyrphplc
AT singlarajeevk experimentaldesignapproachforimpurityprofilingofvalacyclovirrelatedproductsbyrphplc
AT mitraanalava experimentaldesignapproachforimpurityprofilingofvalacyclovirrelatedproductsbyrphplc